Previous issues

STAY CONNECTED

Number 53 March - April 2013 flipbook

» [Editorial] Struck by cancer, killed by ageism » [Cover Story] Richard Sullivan: Why are we doing this? » [Cutting Edge] We hit the spot » [Cross Talk] Centralising cancer services: is this the best way to improve results? » [Best Cancer Reporter Award] Tobacco tactics in the headlines » [e-Grand Round] Skin toxicities caused by targeted therapies » [Focus] Is there an app for that? » [Impact Factor] Aprepitant and control of emesis induced by five-day chemotherapy » [Newsround] Newsround » [My World] My World - Jacob Scott

Number 52 January - February 2013 flipbook

» [Editorial] Time to act on trials » [Cover Story] Vincenzo Valentini: putting knowledge to work » [Cutting Edge] The reoperation lottery » [Systems & Services] Stop Cancer Now! » [Best Cancer Reporter Award] Me and my cancer » [e-Grand Round] Survivor services: supporting patients living with and beyond cancer » [Spotlight on...] Taking the isolation out of isolation » [Impact Factor] Diabetes risk after radiation – not out of the woods » [Newsround] Newsround » [My World] My World

Number 51 November - December 2012 flipbook

» [Editorial] Penalised for having cancer » [Cover Story] Andreas Engert: Learning from Hodgkin’s » [Cutting Edge] Testing the testers » [Cross Talk] Late diagnosis: Why does it happen? How can we do better? » [Best Cancer Reporter Award] The origin of a special success » [e-Grand Round] OECI accreditation: is yours a top-class cancer centre? » [Spotlight on...] Lungscape: a living lung laboratory » [Impact Factor] Gastro-oesophageal cancer –is CROSSing over so hard to do? » [Impact Factor] Cetuximab dosing by rash – is the scaling of EVEREST meaningful? » [Newsround] Newsround » [My World] My World

Number 50 September - October 2012 flipbook

» [Editorial] Personalised medicine: a note of caution » [Cover Story] Siddhartha Mukherjee: explaining cancer » [Cutting Edge] We told you so: How the persistence of immunotherapy researchers is finally paying off » [Cross Talk] Futile care: Why does it happen, how can we avoid it? » [Best Cancer Reporter Award] In the jungle of the miracle healers » [e-Grand Round] How exposure to a mother’s cancer treatment during pregnancy impacts on the child » [Spotlight on...] How bad news can be good news for cancer services » [Impact Factor] For localised prostate cancer, does technology equal progress? » [Impact Factor] Gemtuzumab ozogamicin in acute myeloid leukaemia » [Newsround] Newsround » [My World] My World

Number 49 July - August 2012 flipbook

» [Editorial] Winning or losing? ESO asks the experts » [Systems & Services] Patients pay a price for spending cuts » [Cover Story] Mary Gospodarowicz: Just do it » [e-Grand Round] New accomplishments in breast cancer chemoprevention » [Masterpiece] Breaking Boundaries » [Patient Voice] If you could see it through my eyes... » [Impact Factor] Salvage chemotherapy in gastric cancer – more than a straw? » [Impact Factor] Manufacturer sponsorship bias in economic analyses matters » [Newsround] Newsround

Number 48 May - June 2012 flipbook

» [Editorial] Framing the argument over futile care » [Cover Story] Mahasti Saghatchian: pioneering a quality mark for Europe's cancer centres » [e-Grand Round] Recent trials in osteosarcoma and their implications for future studies » [Cutting Edge] Can the Reverend Bayes help deliver proven therapies for patients with rare cancers? » [Spotlight on...] Fixing the holes in the opioid supply lines » [Systems & Services] Prostate cancer units: it's about options and quality » [Impact Factor] Localised non-bulky Hodgkin lymphoma - future questions » [Impact Factor] First-line bevacizumab for ovarian cancer - new standard of care? » [Newsround] Newsround

Number 47 March - April 2012 flipbook

» [Editorial] Join the battle for biomedical research » [Cover Story] John Crown: Move aside bureaucrats and let us take a lead » [Cutting Edge] International guidelines offer hope of speeding up progress in advanced breast cancer » [e-Grand Round] Endotherapy for Barrett's oesophagus with early neoplasia » [Best Cancer Reporter Award] Living with the timebomb of a childhood cancer » [Spotlight on...] A world-class centre arises from the French ground-zero » [Systems & Services] How are we doing? » [Impact Factor] The importance of local control in pancreatic cancer » [Impact Factor] Time for another rethink on prostate cancer screening » [Newsround] Newsround

Number 46 January - February 2012

» [Editorial] Aspirin for cancer prevention: why wait? » [Cover Story] Stein Kaasa: Let me show you what integrated palliative care can do » [e-Grand Round] Optimising dose-dense regimens for early breast cancer » [Cutting Edge] Picture this: The new imaging techniques that can help doctors select the right treatment at the right time » [Best Cancer Reporter Award] Is hope worth any price? » [Masterpiece] Still waiting for the world to catch up » [Systems & Services] After the treatment's over... » [Impact Factor] The silent minority - unpublished data on cancer care » [Impact Factor] Hodgkin lymphoma - absence of evidence not evidence of absence! » [Newsround] Newsround

Number 45 November - December 2011

» [Editorial] To cut or not to cut? Why surgeons don't have all the answers » [Cover Story] Luzia Travado: improving outcomes for patients by attending to their distress » [e-Grand Round] Prognostic and predictive markers in colorectal cancer: implications for clinical management » [Best Cancer Reporter Award] Hope for me, and for others who come after: Victoria Lambert's award-winning article explores the impact of a new network of early trial centres » [Masterpiece] Redefining the role of pathology: how Giuseppe Viale embraced the new responsibilities of the molecular era » [Systems & Services] Taking the first step on the road to cancer control » [Impact Factor] An important piece of the localised prostate cancer puzzle? » [Impact Factor] Front-line therapy in lung cancer with mutations in EGFR » [Newsround] Newsround

CancerWorld invites you to visit:

European School of Oncology -
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.

Euro-Arab School of Oncology - is a joint initiative between the Egyptian Ministry of Health and Population and ESO. EASO intends to enhance and support education in the oncology field in all the Arab countries.

CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, Boehringer Ingelheim, Celgene, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Helsinn, Merck Serono, Novartis, Roche and Sanofi Aventis.

Cancer World